Zacks Investment Research cut shares of Mesa Laboratories (NASDAQ:MLAB) from a buy rating to a strong sell rating in a research note published on Friday, November 10th.
According to Zacks, “MESA LABORATORIES, INC. designs, develops, acquires, manufactures and markets instruments and systems utilized in connection with industrial applications and hemodialysis therapy. “
Other analysts also recently issued research reports about the stock. TheStreet raised shares of Mesa Laboratories from a c+ rating to a b rating in a research report on Monday, November 6th. BidaskClub downgraded shares of Mesa Laboratories from a hold rating to a sell rating in a report on Monday, July 31st.
Mesa Laboratories (NASDAQ:MLAB) last announced its quarterly earnings data on Monday, November 6th. The medical instruments supplier reported $0.60 EPS for the quarter, missing the consensus estimate of $0.64 by ($0.04). Mesa Laboratories had a return on equity of 9.15% and a net margin of 10.25%. The company had revenue of $22.95 million for the quarter, compared to analyst estimates of $25.50 million. analysts predict that Mesa Laboratories will post 2.47 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 15th. Stockholders of record on Thursday, November 30th will be paid a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.47%. The ex-dividend date is Wednesday, November 29th. Mesa Laboratories’s payout ratio is 23.10%.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Capital Analysts LLC bought a new stake in shares of Mesa Laboratories during the 3rd quarter worth $128,000. SG Americas Securities LLC bought a new stake in shares of Mesa Laboratories during the 3rd quarter worth $131,000. Voya Investment Management LLC bought a new stake in shares of Mesa Laboratories during the 2nd quarter worth $221,000. Westfield Capital Management Co. LP bought a new stake in shares of Mesa Laboratories during the 3rd quarter worth $239,000. Finally, Strs Ohio raised its stake in shares of Mesa Laboratories by 5.6% during the 2nd quarter. Strs Ohio now owns 1,900 shares of the medical instruments supplier’s stock worth $272,000 after purchasing an additional 100 shares during the period. Institutional investors own 69.74% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Zacks Investment Research Downgrades Mesa Laboratories (NASDAQ:MLAB) to Strong Sell” was originally reported by BBNS and is the sole property of of BBNS. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://baseballnewssource.com/markets/mesa-laboratories-inc-mlab-cut-to-strong-sell-at-zacks-investment-research/1773616.html.
About Mesa Laboratories
Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mesa Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories Inc. and related companies with our FREE daily email newsletter.